SILENCE THERAPEUTICS PLC-ADR (SLN) Stock News
NASDAQ:SLN - Nasdaq - US82686Q1013 - ADR - Currency: USD
SLN Latest News, Press Relases and Analysis
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
The consensus price target hints at a 556.2% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
The mean of analysts' price targets for Silence Therapeutics (SLN) points to a 590.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying
We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain […]
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
Silence Therapeutics just reported results for the second quarter of 2024.
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Silence Therapeutics (NASDAQ:SLN) just reported results for the second quarter ...
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
The 3 Best Gene Editing Stocks to Buy in August 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.
